Curis Starts Roche Sponsored Study for AML and MDS

mia.burns Curis Announces Initiation of a Roche-Sponsored Phase 1b/2 Study of Erivedge(R) (vismodegib) in Relapsed/Refractory AML and High Risk MDS AML and MDS Represent Non-Mutation ...

A Thaw Between Roche And Novartis? What About A Merger?

esilverman Will Roche and Novartis work more closely together and even consider a merger? Now that both drugmakers have new chairmen – replacing a pair who had famously icy ...

Roche Report High Response Rate in Lung Cancer Drug Trial

barbara.lempert Roche presents updated data on investigational cancer immunotherapy MPDL3280A (anti-PDL1) in lung cancer at ECC 2013 Rapid and durable responses observed in ...

PacBio soars in wake of $75M Dx deal with Roche

Mark Hollmer Struggling gene sequencer Pacific Biosciences saw its stock rocket upward in the wake of a diagnostics development deal with industry giant Roche that's worth as much ...

Roche lung cancer drug bags another ‘breakthrough’ at the FDA

John Carroll Roche has won bragging rights to the FDA's new Breakthrough Therapy designation for its ALK inhibitor alectinib, a non-small cell lung cancer drug which will be featured ...

Roche lung cancer hopeful wins FDA ‘breakthrough’ tag

Tracy Staton That makes two "breakthrough" tags for the Swiss drugmaker so far. FiercePharma News

German airline exec to join Roche as chairman

Alok Saboo FierceBiotech News

EU body endorses 11 new drugs from Glaxo, Roche, J&J and others

Ryan McBride A European Union regulator has recommended approval of 11 new drugs for a range of diseases such as HIV, breast cancer and diabetes. And the nods could lead to final approvals ...

Glaxo, Roche, J&J and others score backing on big day for EU regulator

Carly Helfand Friday, the EU's Committee for Medicinal Products for Human Use (CHMP) recommended 11 new drugs for a variety of diseases–the most nods it's given in a single ...

BioMarin spike fades as Roche CEO guns down latest takeover rumor

John Carroll Another day, another buyout rumor. Today it's BioMarin's turn in the takeover spotlight, after Dealreporter broke a story claiming that Roche is now scouting for ...

Roche chief tamps down talk of $13.5B BioMarin buyout

Tracy Staton Roche CEO Severin Schwan put the kibosh on chatter about its supposed plans to raise funding for a BioMarin Pharmaceutical buyout. According to Dealreporter, the Swiss ...

FDA approves Teva’s generic of Roche blockbuster Xeloda

Eric Palmer Roche's blockbuster Xeloda went off patent in December, so it was inevitable that a generic would hit the market at some point. It just wasn't known when. Well, ...
Page 3 of 712345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS